Interpace Biosciences Performance

IDXGDelisted Stock  USD 2.20  0.00  0.00%   
The company retains a Market Volatility (i.e., Beta) of -1.05, which attests to a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Interpace Biosciences are expected to decrease slowly. On the other hand, during market turmoil, Interpace Biosciences is expected to outperform it slightly. Interpace Biosciences right now retains a risk of 0.0%. Please check out Interpace Biosciences potential upside, as well as the relationship between the kurtosis and market facilitation index , to decide if Interpace Biosciences will be following its current trending patterns.

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Interpace Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Interpace Biosciences is not utilizing all of its potentials. The newest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Begin Period Cash Flow3.4 M
Total Cashflows From Investing Activities-315 K
  

Interpace Biosciences Relative Risk vs. Return Landscape

If you would invest  220.00  in Interpace Biosciences on August 29, 2024 and sell it today you would earn a total of  0.00  from holding Interpace Biosciences or generate 0.0% return on investment over 90 days. Interpace Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Interpace, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  

Interpace Biosciences Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Interpace Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Interpace Biosciences, and traders can use it to determine the average amount a Interpace Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
IDXG
Based on monthly moving average Interpace Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Interpace Biosciences by adding Interpace Biosciences to a well-diversified portfolio.

Interpace Biosciences Fundamentals Growth

Interpace OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Interpace Biosciences, and Interpace Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Interpace OTC Stock performance.

About Interpace Biosciences Performance

By analyzing Interpace Biosciences' fundamental ratios, stakeholders can gain valuable insights into Interpace Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Interpace Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Interpace Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.

Things to note about Interpace Biosciences performance evaluation

Checking the ongoing alerts about Interpace Biosciences for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Interpace Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Interpace Biosciences is not yet fully synchronised with the market data
Interpace Biosciences has a very high chance of going through financial distress in the upcoming years
Interpace Biosciences currently holds 9.44 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 41.31 M. Net Loss for the year was (14.94 M) with profit before overhead, payroll, taxes, and interest of 17.95 M.
Interpace Biosciences currently holds about 1.86 M in cash with (8.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Roughly 28.0% of Interpace Biosciences shares are held by company insiders
Evaluating Interpace Biosciences' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Interpace Biosciences' otc stock performance include:
  • Analyzing Interpace Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Interpace Biosciences' stock is overvalued or undervalued compared to its peers.
  • Examining Interpace Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Interpace Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Interpace Biosciences' management team can help you assess the OTC Stock's leadership.
  • Pay attention to analyst opinions and ratings of Interpace Biosciences' otc stock. These opinions can provide insight into Interpace Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Interpace Biosciences' otc stock performance is not an exact science, and many factors can impact Interpace Biosciences' otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Consideration for investing in Interpace OTC Stock

If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk